Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.

Key facts

Study ID

NCT01103726

Run by

Pfizer

People needed

34

Starts

2010-05-01

Expected to finish

2011-11-01

Last updated by the study team

2011-11-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy right-handed male and female subjects between the ages of 18 and 55 years, inclusive
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
• An informed consent document signed and dated by the subject
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

You may not qualify if…

• Women of reproductive potential
• History of agranulocytosis or movement disorder
• Positron Emission Tomography (PET) or Magnetic Resonance Imaging (MRI) contraindications

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.